Microarrays Inc. this week launched three MI PathArray assays for studying targeted biological pathways. The new arrays cover pathways associated with apoptosis, growth factors, and inflammation. Each slide contains four subarrays with an average coverage of three probes per gene plus controls and probes for data normalization. On its website, MI says it plans to introduce arrays for studying cancer and transcription factors in the future. The company also plans to eventually sell kits and hardware for sample preparation, processing, and array hybridization.
BioArray News spoke with CEO Joel Peek about the new offering earlier this month (BAN 10/11/11).